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SUMMARY
This study was aimed to evaluate and compare the pathogenicity of rabies virus isolated from bats and dogs, and to verify the 
efficacy of a commercial rabies vaccine against these isolates. For evaluation of pathogenicity, mice were inoculated by the intramuscular 
route (IM) with 500MICLD50/0.03mL of the viruses. The cross-protection test was performed by vaccinating groups of mice by the 
subcutaneous route and challenged through the intracerebral (IC) route. Isolates were fully pathogenic when inoculated by the IC 
route. When inoculated intramuscularly, the pathogenicity observed showed different death rates: 60.0% for the Desmodus rotundus 
isolate; 50.0% for dog and Nyctinomops laticaudatus isolates; 40.0% for Artibeus lituratus isolate; 9.5% Molossus molossus isolate; 
and 5.2% for the Eptesicus furinalis isolate. Mice receiving two doses of the vaccine and challenged by the IC route with the isolates 
were fully protected. Mice receiving only one dose of vaccine were partially protected against the dog isolate. The isolates from bats 
were pathogenic by the IC route in mice. However, when inoculated through the intramuscular route, the same isolates were found 
with different degrees of pathogenicity. The results of this work suggest that a commercial vaccine protects mice from infection with 
bat rabies virus isolates, in addition to a canine rabies virus isolate.
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INTRODUCTION
The Lyssavirus genus includes 11 recognized species17. The rabies 
virus (RABV) is found in various domestic animals but also in bats. The 
Lagos bat virus (LBV), Mokola virus (MOKV) and the Duvenhage virus 
(DUVV) have been isolated in bats, domestic animals and humans in 
Africa21. European bat lyssaviruses 1 and 2 (EBLV1 and EBL2) have been 
isolated from insectivorous bats in Europe14. Australian bat lyssavirus 
(ABLV) circulates in Australia among insectivorous and pteropid bats and 
has caused cases of human rabies35. Recently, four new lyssavirus species 
were isolated from bats in Eurasia and were ratified by the International 
Committee on Virus Taxonomy (ICTV Official Taxonomy: Updates 
since the 8th Report)17: the Irkut (IRKV)5 Aravan (ARAV)1, Khujand 
(KHUV)22 and the West Caucasian bat virus (WCBV)5. KUZMIN et al., 
201021 described the isolation and characterization of a new lyssavirus, 
which should be considered a new species of the genus. Based on 
phylogeny, serological cross-reactivity, and peripheral pathogenicity to 
mice, lyssaviruses can be placed into two phylogroups2. Phylogroup I 
includes RABV, DUVV, EBL1, EBL2, ABLV, ARAV, KHUV and IRKV. 
Phylogroup II includes LBV and MOKV. The WCBV cannot be included 
in any of these phylogroups, and was suggested that it be considered as 
a member of an independent phylogroup III16,20. Viruses of phylogroup 
I have been shown to be pathogenic for mice when inoculated via the 
intracerebral (IC) and intramuscular (IM) routes. Members of phylogroup 
II were shown to be pathogenic for mice only when inoculated via the 
IC route2. 
In Brazil, dog-transmitted rabies has been reduced by an aggressive 
vaccination program30; however, bat-transmitted rabies (particularly 
the Desmodus rotundus) remains endemic, especially in Northern and 
Northeastern states26,33. According to the data of Brazilian Ministry of 
Health27, in 2010 (until April) occurred one case of human rabies in 
the state of Rio Grande do Norte, and the source was associated to bat 
transmission; in 2009, two cases in the state of Maranhão due to dog 
transmission; in 2008, there were two cases transmitted by vampire 
bats respectively in Pernambuco and Goiás State, and one marmoset-
transmitted case in Ceará; in 2007 there was one case of dog-transmitted 
rabies in Maranhão; in 2006 there were nine cases due to dogs and 
vampire bats, six in the state of Maranhão, and respectively one case in 
the states of Pernambuco, Alagoas, Minas Gerais and Rio de Janeiro. In 
the year of 2005, there were reported 42 human rabies cases transmitted 
by vampire bats, one dog and one due to marmoset transmission. In the 
majority of these human cases, the possible animal species were drawn 
based on genetic sequencing analyses of the isolates. 
 A panel of monoclonal antibodies to rabies virus collections from 
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Brazil has identified two major variants, one associated with dogs and 
other with vampire bats (Desmodus rotundus), as well as other variants 
associated with several insectivorous bats and common marmosets 
(Callithrix jacchus jacchus)4,12. Genetic characterization of Brazilian 
rabies virus isolates, by sequencing of partial or complete N gene18,34, 
P gene4, and G genes sequences31 also identified two principal variants 
maintained by vampire bats and dogs. However, a molecular analysis 
performed with viruses of insectivorous bats identified three variants 
of rabies virus19. Thus, rabies virus isolates from the frugivorous bats 
(Artibeus sp.) were found to be closely related to those viruses isolated 
from D. rotundus vampire bats19,34. All these studies have demonstrated 
that the rabies virus isolates from Brazil belonged to genotype 1 of rabies 
virus. However, little is known about the biological characteristics of 
these isolates and about the ability of current rabies vaccines to elicit 
immune responses which would provide cross-protection. The inactivated 
commercial rabies virus vaccines for human and animal use, such as 
the Pitman Moore (PM), Pasteur virus (PV), and Flury Lep (LEP), all 
belong to genotype 1. These vaccines induce immunity against viruses 
of the phylogroup I but fail to protect against viruses of the genotype 
2 and 32,6,23,24 and WCBV16. Failures of protection in mice by Brazilian 
vaccines against wild rabies viruses were reported36. 
The purpose of this study was to evaluate and to compare the 
pathogenicity of several isolates of rabies viruses isolated from 
hematophagous, frugivorous, and insectivorous bats with the rabies 
virus isolated from dog, and the efficacy of a commercially available 
rabies vaccine against these isolates. The experiments were performed 
in a mice model.
MATERIALS AND METHODS
Canine rabies virus isolate (BR-C) used in this experiment 
corresponded to one of the isolates of the 1992’s dog rabies epidemic 
registered in the municipality of Araçatuba, São Paulo. Five bats isolates 
were chosen based on the nucleocapsid (NC) differences of the several 
independent lineages of bat rabies viruses in Brazil. One lineage consisted 
of a vampire bat (Desmodus rotundus BR-DR1), and also including the 
isolate from a frugivorous bat (Artibeus lituratus BR-AL3). Other three 
lineages consisted of insectivorous bat isolates; namely the Eptesicus 
sp. (BR-EF1), Molossus sp. (BR-MM1) and Nyctinomops sp. (BR-EF1) 
isolates19. The source of each virus isolate is summarized in Table 1. 
Brain samples were diagnosed as rabies-positive by both the fluorescent 
antibody test (FAT) and mouse inoculation test (MIT). All isolates were 
collected from the brain tissue and passed five times in suckling mouse 
brain using IC inoculation.
The titers of the viral isolates were determined by IC inoculations of 
tenfold virus dilutions into 4-week-old mice, and 50% mouse IC lethal 
dose (MICLD50) was calculated using the Reed and Müench method29.
Four-week-old mice were used for pathogenicity and cross protection 
tests. 
Mice were provided by the LANAGRO-SP (Laboratório Nacional 
Agropecuário de São Paulo), and were housed and handled with ethical 
principles in animal research adopted by the Bioethics Commission of 
the Faculty of Veterinary Medicine and Zootechny of University of São 
Paulo (protocol number 263/2003) .
For evaluation of pathogenicty, one group of Swiss female mice 
(n = 20), 6 week-old, were injected by IM route in the thigh (0.1 mL) 
with 500MICLD50/0.03mL of each viral isolates. Control mice were 
injected using the virus diluent containing 2% inactivated horse serum 
in distilled water and antibiotics. These mice were observed for signs of 
rabies for a minimum of 30 days.
For the immunization of mice, a veterinary commercially available 
Pasteur virus (PV-strain) propagated in BHK-21 cells, chemically 
inactivated and containing an adjuvant was kindly provided by the 
Biovet® (RAI-VET - lot no. 466/04). The vaccine titer informed was 3.42 
international unit (IU)/dose/mice of 2.0 mL and the vaccine had been 
approved by the LANAGRO (Brazilian Official Vaccine Testing Laboratory 
from the Brazilian Ministry of Agriculture, Livestock and Supply).
The mouse intracerebral lethal dose 50% (MICLD50/0.03mlL was 
determined by injecting 0.03 mL of BR-C, BR-EF1, BR-NL1, BR-AL3, 
BR-MM1, and BR-DR1, in each group consisting of 4 week-old Swiss 
female mice (n = 8) by the IC route.
For mouse protection studies, 14 groups of six 4-week-old female 
Swiss mice each were used. We administered 0.2 mL of the commercial 
inactivated rabies vaccine by the subcutaneous route on day 0 to all 
groups. A week later, seven groups were inoculated with a second dose 
(0.2 mL) of the same vaccine. All vaccinated groups were challenged 
14 days after the first dose of vaccine, together with an equal number 
of unvaccinated control mice, with tenfold dilution of BR-C, BR-EF1, 
BR-NL1, BR-AL3, BR-MM1, and BR-DR1 isolates, by the IC route. 
Lethal dose (LD50) endpoints in vaccinated and unvaccinated control 
mice were determined by the modified Habel technique15 and calculated 
by the Reed and Müench method29. The degree of protection (protection 
index) in mice challenged by the IC route was determined by subtracting 
the logarithm of the LD50 endpoint in vaccinated mice from that of the 
control mice. A difference of 3 or log 1000 indicated vaccine protection.
RESULTS
Susceptibility: The field isolates BR-C, BR-EF1, BR-NL1, BR-
AL3, BR-MM1, and BR-DR1 were fully pathogenic when inoculated 
Table 1
Field isolates of rabies virus used in pathogenicity and vaccine protection 
tests, according to the original host, year of isolation and GenBank accession 
numbers
Isolates Original host Year of 
isolation
Accession 
numbers*
BR-C Dog 1992 -
BR-EF1 Bat (Eptesicus furinalis) 1998 AB201811
BR-NL1 Bat (Nyctinomops 
laticaudatus)
1998 AB201806
BR-AL3 Bat (Artibeus lituratus) 1998 AB117971
BR-MM1 Bat (Molossus molossus) 1999 AB201815
BR-DR1 Bat (Desmodus rotundus) 2000 AB201803
* Sequences retrieved from GenBank.
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in mice by the IC route, all leading to 100% mortality. However, when 
injected intramuscularly with a dose 0.1 mL of 500MICLD50/0.03mL, 
the pathogenicity observed among the viruses showed different mortality 
rates: 60.0% for the D. rotundus isolate; 50.0% for dog and Nyctinomops 
laticaudatus isolates; 40.0% for A. lituratus isolate; 9.5% Molossus 
molossus isolate; and 5.2% for the Eptesicus furinalis isolate. 
Mouse protection studies: The protective indices of vaccinated mice 
challenged by IC route with the isolates were summarized in Table 2. 
Mice receiving two shots of vaccine and challenged intracerebrally were 
protected against all the isolates, and mice receiving only one shot were 
partially protected against the dog isolate (BR-C). 
DISCUSSION
Bats living in rural and urban areas are a complex problem with 
economic, public health and ecological implications. Rabies virus 
infected bats found in these environments pose a risk to both humans 
and domestic animals. In fact, in Brazil, there are reports of vampire bats 
feeding on the domestic dogs from an urban area of Olinda-Pernambuco8 
and Rio de Janeiro10,11. SCHAEFER et al.32 (2002) described, in south 
of Brazil, a cat rabies isolate found in an area free of urban rabies since 
1990 and related that rabies virus could be associated to a bat-related 
virus. The number of rabid bats detected, mainly in non-hematophagous 
species, increases each year, due to the increased diagnoses of rabies 
in bats from the heavy urbanized areas, reflecting the more active 
surveillance on rabies in non-hematophagous bats. A study describing 
the detection of bat rabies in the north-northwestern regions of the State 
of Sao Paulo-Brazil showed that in 7.9% of the cases, bats had contact 
with humans or domestic animals and in 17.4%, attacked humans and 
animals7. Thus, genetic and biological studies of these isolates would 
contribute to a better understanding of the bat rabies epidemiology, as well 
as indicate new ways to prevent the disease in man and animals. With the 
objective to elucidate some of these questions, the present study analyzed 
the pathogenicity of the rabies virus isolates obtained from a vampire, 
frugivorous, insectivorous bats and from a dog, using the mice model. 
The efficacy of a commercially available inactivated rabies vaccine was 
assessed using these isolates as a challenge virus. 
Previous studies suggested that phylogroup II lyssaviruses were not 
pathogenic when inoculated peripherally. These assertions suggested 
that such viruses are generally less pathogenic, and imply that they 
have limited public health and veterinary significance2. In this work 
we have evaluated the susceptibility of mice to various isolates for 
hematophagous, frugivorous and insectivorous bats in comparison to a 
virus isolate from a dog. We showed that all isolates of rabies virus used 
in this experiment were pathogenic by the IC route in mice. However, 
when 500MICLD50 were inoculated through the IM route, the isolates 
were found with different degrees of pathogenicity. When inoculated 
by the IM route the bat rabies isolates BR-DR1, BR-NL1 and BR-AL3 
demonstrated almost the same pathogenicity of the dog (BR-C) isolate. 
On the other hand, rabies virus isolates from the insectivorous bat E. 
furinalis (BR-EF1) and M. molossus (BR-MM1) were less pathogenic. 
MORIMOTO et al.28 (1996) compared the biological properties of 
rabies virus isolates of the silver-haired bat (SHBRV) to those of the 
coyote isolates (COSRV) and found that SHBRV is less neurovirulent 
than COSRV, when administered by the IM route, whereas both viruses 
were equally neuroinvasive when injected intracranially. BADRANE et 
al.2 (2001) investigated the biological significance of the phylogrouping 
in relation to the pathogenicity and immunogenicity of the lyssaviruses 
and found that when inoculated in adult mice, genotype 1 and 6 viruses 
(phylogroup I) were pathogenic by both the IC and IM routes and 
genotype 2 and 3 viruses (phylogrup II) were only pathogenic by IC 
route. Lagos bat virus (LBV) was reported to have markedly reduced 
levels of peripheral pathogenicity2. MARKOTTER et al.25 (2009) suggest 
that this affirmative was based on a study of one isolate of LBV and 
demonstrated that peripheral pathogenicity of representatives of LBV in 
a murine model is as high as that of the rabies virus. In the same way, in 
this study regarding the observed decreased virulence, the fact must be 
analyzed carefully, since only one isolate of BR-EF1 and BR-MM1 was 
studied. Thus, we suggest that future studies should be accomplished, 
including rabies virus isolates isolated from different species of bats to 
provide a better resolution.
In the present study we verified the protection in mice conferred by 
an inactivated veterinary vaccine and challenged with field rabies virus 
isolates. Some failures of protection in mice, following experimental 
immunizations have been reported13,23,36. In this work we verified that 
the vaccine protected mice against the IC challenge, with isolates from 
bats and a dog. Mice receiving a single dose of the same vaccine were 
Table 2
Protection of mice vaccinated with a commercial inactivated PV-rabies vaccine and challenged by the IC route with field isolates rabies virus
Challenge virus ICLD50 
log 10 
Control
ICLD50 
log 10 
Vaccinated 2 doses
ICLD50 
log 10 
Vaccinated 1 dose
Protection index (PI)a
log 10
2 doses 1 dose
BR-C 5.9 1.0 4.3 4.9 1.6
BR-EF1 5.5 <1.0 1.4 5.5 4.1
BR-NL1 5.2 <1.0 1.0 5.2 4.2
BR-AL3 4.8 1.0 1.8 3.8 3.0
BR-MM1 4.7 <1.0 1.0 4.7 3.7
BR-DR1 5.3 <1.0 2.0 5.3 3.3
a) The degree of protection (protection index), in mice challenged by IC route was determined by subtracting the logarithm of the LD50 endpoint in vaccinated mice 
from that of the control mice.
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found to be only partially protected against the challenge with a dog 
isolate. Other studies showed that animal vaccines protected mice against 
challenges with Duvenhage and Lagos bat viruses and isolates derived 
from various species of bats13. DIETZSCHOLD & HOOPER9 (1998) 
reported that commercial vaccines licensed for use in humans protected 
mice against silver-haired bat rabies virus. However, immunization with 
P-G gene of rabies virus did not protect against viruses from genotypes 
3 and 22. LAFON et al.23 (1988), however, showed that inactivated 
vaccine prepared with PV strain protected the mice challenged with 
a German bat isolate (Duvenhage), but PM or LEP vaccines did not 
protect mice against the virus infection. The potency of an inactivated 
animal rabies vaccine for domestic animals by using two types of potency 
tests; namely the traditional NIH and the CDC test (mice vaccinated 
once and challenged by the IM route) indicated that protection was 
highest against raccoon and bat viruses when compared with protection 
conferred against isolates of skunk, coyote and fox3. HANLON et al.16 
(2005) showed reduced protection with vaccination with conventional 
rabies vaccine against four new rabies viruses from bats in Eurasia. 
Studies performed with field isolates in Brazil showed differences in 
the degree of protection provided by immunization with PV vaccine and 
challenged with bovine rabies virus isolates (vampire bat virus lineage)36. 
Although belonging to genotype 1, these isolates turned out to be the 
most divergent among American and Brazilian rabies viruses studied by 
genetic characterization36. Nevertheless, data related to vaccine cross-
protection have not been reported for rabies virus isolated from bats in 
Brazil. The results of this work suggest that PV vaccine protects mice 
from infection with vampire, frugivorous and insectivorous bat rabies 
viruses in addition to a canine rabies virus. Studies on the cross-protection 
to rabies virus in mice, conferred by a rabies vaccine are controversial 
and perhaps they do not represent what really takes place in nature with 
the species involved. The results often depend on the type of vaccine 
used as well as on the number of isolates tested. 
At present, little is known about the epidemiology of the rabies 
virus in bats in Brazil and the country’s surveillance systems need to 
assess the potential implications and the impact in public health and in 
veterinary public health. 
RESUMO
Patogenicidade de diferentes isolados do vírus da raiva e teste de 
proteção em camundongos vacinados
O estudo avaliou e comparou as propriedades patogênicas de cinco 
isolados do vírus da raiva de morcegos e um isolado do vírus da raiva 
de cão e analisou a eficácia de vacina comercial contra estes isolados, 
em camundongos. Para o estudo de patogenicidade camundongos foram 
inoculados pela via IM com 0,1 mL contendo 500MICLD50/0,03mL 
das amostras de vírus. Quando inoculados pela via IC, os isolados do 
vírus da raiva provocaram a morte de 100% dos camundongos. No 
entanto, 500MICLD50/0,03mL das mesmas amostras, inoculadas pela 
via IM, ocasionaram mortalidade de: 60,0% quando a amostra era de 
Desmodus rotundus; 50,0% de cão e de Nyctinomops laticaudatus; 
40,0% de Artibeus lituratus; 9,5% de Molossus molossus; e 5,2% de 
Eptesicus furinalis. Camundongos que receberam duas doses de vacina 
foram protegidos quando desafiados pela via IC, com todas as amostras 
testadas. Quando os camundongos receberam uma dose da mesma 
vacina, houve proteção parcial daqueles desafiados com a amostra de 
cão. Todos os isolados do vírus da raiva testados foram patogênicos para 
camundongos, inoculados pela IC. No entanto, pela via IM, os mesmos 
isolados mostraram diferentes graus de patogenicidade. Concluiu-se 
também que a vacina comercial contra raiva protegeu os camundongos 
desafiados com amostras de vírus isolados de morcegos e de cão.
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